Introduction: Dacomitinib is an epidermal growth factor receptor (EGFR) inhibitor approved for the treatment of metastatic non-small cell lung cancer (NSCLC) in the first line in patients with EGFR activating mutations. Dacomitinib is taken orally once daily at 45 mg with or without food. until disease progression or unacceptable toxicity occurs. Oncology patients often can develop ga... https://iguanasellers.shop/product-category/ballpoint-pen/